PharmaCyte Biotech, Inc. (PMCB) stock
PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
$6.68−0.92 (-12.11%)
Close on Nov 13, 2026Market cap $71.71MP/E –Yield –
PharmaCyte Biotech total assets
Total assets on the balance sheet at the end of each period.
PharmaCyte Biotech's total assets was $36.71M at Jul 31, 2026. For fiscal 2026 it was $46.75M, down 15.3% from the year before. Over ten years it grew 20.6% a year on average. The highest annual figure on record is $90.62M in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | $46.75M | -15.3% |
| FY2025 | Apr 30, 2025 | $55.17M | -7.9% |
| FY2024 | Apr 30, 2024 | $59.90M | -18.3% |
| FY2023 | Apr 30, 2023 | $73.28M | -19.1% |
| FY2022 | Apr 30, 2022 | $90.62M | +1124.0% |
| FY2021 | Apr 30, 2021 | $7.40M | +20.1% |
| FY2020 | Apr 30, 2020 | $6.17M | +6.6% |
| FY2019 | Apr 30, 2019 | $5.78M | -9.8% |
| FY2018 | Apr 30, 2018 | $6.41M | -26.0% |
| FY2017 | Apr 30, 2017 | $8.67M | +21.0% |
| FY2016 | Apr 30, 2016 | $7.16M | -23.0% |
| FY2015 | Apr 30, 2015 | $9.30M | -0.2% |
| FY2014 | Apr 30, 2014 | $9.32M | +223.8% |
| FY2013 | Apr 30, 2013 | $2.88M | +37.8% |
| FY2012 | Apr 30, 2012 | $2.09M | +68.3% |
| FY2011 | Apr 30, 2011 | $1.24M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | $36.71M | -33.5% |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | $46.75M | +6.7% |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | $55.87M | +1.4% |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | $55.98M | -20.3% |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | $55.17M | -7.9% |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | $43.83M | -38.6% |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | $55.10M | -30.1% |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | $70.19M | -12.1% |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | $59.90M | -18.3% |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | $71.36M | -8.5% |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | $78.88M | -4.2% |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | $79.88M | -8.6% |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | $73.28M | -19.1% |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | $77.95M | -15.2% |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | $82.35M | -10.8% |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | $87.39M | +1216.6% |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | $90.62M | +1124.0% |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | $91.94M | +1012.9% |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | $92.31M | +932.4% |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | $6.64M | -10.7% |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | $7.40M | +20.1% |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | $8.26M | +54.8% |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | $8.94M | +67.5% |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | $7.43M | +32.6% |
| Q4 FY2020CQ1 2020 | Apr 30, 2020 | $6.17M | +6.6% |
| Q3 FY2020CQ4 2019 | Jan 31, 2020 | $5.34M | -8.5% |
| Q2 FY2020CQ3 2019 | Oct 31, 2019 | $5.34M | -12.0% |
| Q1 FY2020CQ2 2019 | Jul 31, 2019 | $5.61M | -20.8% |
| Q4 FY2019CQ1 2019 | Apr 30, 2019 | $5.78M | -9.8% |
| Q3 FY2019CQ4 2018 | Jan 31, 2019 | $5.84M | -13.2% |
| Q2 FY2019CQ3 2018 | Oct 31, 2018 | $6.07M | -23.4% |
| Q1 FY2019CQ2 2018 | Jul 31, 2018 | $7.08M | -25.7% |
| Q4 FY2018CQ1 2018 | Apr 30, 2018 | $6.41M | -26.0% |
| Q3 FY2018CQ4 2017 | Jan 31, 2018 | $6.73M | -11.7% |
| Q2 FY2018CQ3 2017 | Oct 31, 2017 | $7.92M | +17.6% |
| Q1 FY2018CQ2 2017 | Jul 31, 2017 | $9.52M | +26.6% |
| Q4 FY2017CQ1 2017 | Apr 30, 2017 | $8.67M | – |
| Q3 FY2017CQ4 2016 | Jan 31, 2017 | $7.61M | – |
| Q2 FY2017CQ3 2016 | Oct 31, 2016 | $6.73M | – |
| Q1 FY2017CQ2 2016 | Jul 31, 2016 | $7.52M | – |
See a number that looks wrong?